Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, WA, United States; Clinical Research Division, Fred Hutchinson Cancer Research Division, Seattle, WA, United States.
Clinical Research Division, Fred Hutchinson Cancer Research Division, Seattle, WA, United States.
Oral Oncol. 2022 Apr;127:105774. doi: 10.1016/j.oraloncology.2022.105774. Epub 2022 Feb 24.
The main objective of our study was to understand the impact of immune cell composition and the tumor-reactivity of tumor infiltrating lymphocytes (TIL) in HPV-positive (HPV) and HPV-negative (HPV) head and neck squamous cell carcinoma (HNSCC). TIL cultures were established from primary HNSCC tumors, the T cell subsets were phenotypically characterized using flow cytometry, and Interferon (IFN)-γ ELISA assay was used to determine TIL function. NanoString Immune Profiler was used to determine an immune signature by HPV-status, and multiplex immunohistochemistry (MIHC) was used to quantify immune cell distributions and their spatial relationships. Results showed that HPV and HPV HNSCC had similar capacity to expand IFN-γ reactive TIL populations, and these TIL populations had similar characteristics. NanoString analysis revealed increased differential expression of genes related to B cell functions in HPV HNSCC, which were significant at a Benjamini-Yekutieli adjusted p-value of < 0.001. MIHC also displayed increased CD8 T cell and CD19/CD20 B cell densities in the tumor region of HPV HNSCC as opposed to HPV HNSCC (p < 0.01). Increases in a combined metric of tumor B cell content and stromal plasma cell content was associated with increased progression-free survival in HPV HNSCC patients treated with immune checkpoint inhibitor therapy (p = 0.03). In summary, TIL populations expanded from HPV and HPV HNSCC displayed similar IFN-γ reactivity. However, we identified a strong B-cell signature present within HPV HNSCC, and higher B and plasma cell content associated with improved PFS in HPV HNSCC patients treated with immune checkpoint inhibitors.
我们研究的主要目的是了解 HPV 阳性(HPV)和 HPV 阴性(HPV)头颈部鳞状细胞癌(HNSCC)中免疫细胞组成和肿瘤浸润淋巴细胞(TIL)的肿瘤反应性的影响。从原发性 HNSCC 肿瘤中建立 TIL 培养物,使用流式细胞术对 T 细胞亚群进行表型特征分析,并使用干扰素(IFN)-γ ELISA 测定 TIL 功能。NanoString 免疫分析器用于根据 HPV 状态确定免疫特征,并用多重免疫荧光化学(MIHC)定量免疫细胞分布及其空间关系。结果表明,HPV 和 HPV HNSCC 具有相似的扩展 IFN-γ 反应性 TIL 群体的能力,并且这些 TIL 群体具有相似的特征。NanoString 分析显示 HPV HNSCC 中与 B 细胞功能相关的基因表达差异增加,在 Benjamini-Yekutieli 调整的 p 值<0.001 时具有统计学意义。MIHC 还显示 HPV HNSCC 肿瘤区域的 CD8 T 细胞和 CD19/CD20 B 细胞密度增加,而 HPV HNSCC 则没有(p<0.01)。肿瘤 B 细胞含量和基质浆细胞含量的综合指标增加与接受免疫检查点抑制剂治疗的 HPV HNSCC 患者的无进展生存期增加相关(p=0.03)。总之,从 HPV 和 HPV HNSCC 扩增的 TIL 群体显示出相似的 IFN-γ 反应性。然而,我们在 HPV HNSCC 中鉴定出一个强烈的 B 细胞特征,并且较高的 B 和浆细胞含量与接受免疫检查点抑制剂治疗的 HPV HNSCC 患者的 PFS 改善相关。